European Journal of Cancer
Volume 39, Issue 7 , Pages 861-869 , May 2003

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women

Received 14 February 2002 ,Revised 17 October 2002 ,Accepted 15 November 2002.

References 

  1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma (suggestions for a new method of treatment with illustrative cases). Lancet. 1896;2:104–107
  2. Furr BJ. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, ‘Zoladex’. Horm. Res. 1989;32(Suppl. 1):86–92
  3. Veronesi U, Pizzocaro G, Rossi A. Oophorectomy for advanced carcinoma of the breast. Surg. Gynecol. Obstet. 1975;141:569–570
  4. Ingle JN, Krook JE, Green SJ, et al.  Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol. 1986;4:178–185
  5. Oriana S, Bohm S, Baeli A, Scavone G, Riboldi G, Torri A. Clinical response and survival according to estrogen receptor levels after bilateral ovariectomy in advanced breast cancer. Eur. J. Surg. Oncol. 1989;15:39–42
  6. Conte CC, Nemoto T, Rosner D, Dao TL. Therapeutic oophorectomy in metastatic breast cancer. Cancer. 1989;64:150–153
  7. Klijn JG, de Jong FH. Treatment with a leuteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1982;1:1213–1216
  8. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br. J. Cancer. 1986;53:629–636
  9. Jonat W. Zoladex™ versus CMF adjuvant therapy in pre/perimenopausal breast cancer (tolerability and amenorrhoea comparisons). Proceedings of ASCO. 2000;19:87a; [abstr 333]
  10. Kaufmann M, Jonat W, Kleeberg U, et al.  Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 1989;7:1113–1119
  11. Williamson K, Robertson JF, Ellis IO, Elston CW, Nicholson RI, Blamey RW. Effect of LHRH agonist, Zoladex, on ovarian histology. Br. J. Surg. 1988;75:595–596
  12. Robertson JF, Walker KJ, Nicholson RI, Blamey RW. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer. Br. J. Surgery. 1989;76:1262–1265
  13. Cohen I, Tepper R, Figer A, Flex D, Shapira J, Beyth Y. Successful co-treatment with LHRH-agonist for ovarian over-stimulation and cystic formation in premenopausal tamoxifen exposure. Breast Cancer Res. Treat. 1999;55:119–125
  14. Nicholson RI, Walker KJ, McClelland RA, Dixon A, Robertson JF, Blamey RW. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer. J. Steroid Biochem. Mol. Biol. 1990;37:989–995
  15. Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer. 1992;28A:810–814
  16. Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M. Survival data relating to the use of goserelin depot in the treatment of premenopausal advanced breast cancer. Eur. J. Cancer. 1993;29A:1498
  17. Taylor CW, Green S, Dalton WS, et al.  Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer (an intergroup study). J. Clin. Oncol. 1998;16:994–999
  18. Harvey HA, Lipton A, Max DT, Pearlman HG, Diaz-Perches R, de la Garza J. Medical castration produced by the GnRH analogue leuprolide to treat metastatic breast cancer. J. Clin. Oncol. 1985;3:1068–1072
  19. Dowsett M, Mehta A, Mansi J, Smith IE. A dose-comparative endocrine-clinical study of leuprorelin in premenopausal breast cancer patients. Br. J. Cancer. 1990;62:834–837
  20. Dowsett M, Jacobs S, Aherne J, Smith IE. Clinical and endocrine effects of leuprorelin acetate in pre- and postmenopausal patients with advanced breast cancer. Clin. Ther. 1992;14(Suppl. A):97–103
  21. Untch M. Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group. Zentralbb Gynakol. 1998;120:284–292
  22. Lissoni P, Barni S, Crispino S, Cattaneo G, Tancini G. Endocrine and clinical effects of an LHRH analogue in pretreated advanced breast cancer. Tumori. 1988;74:303–308
  23. Klijn JG, de Jong FH, Lamberts SW, Blankenstein MA. LHRH-agonist treatment in clinical and experimental human breast cancer. J. Steroid Biochem. 1985;23:867–873
  24. Klijn JG, Beex LV, Mauriac L, et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer (a randomized study). J. Natl. Cancer Inst. 2000;92:903–911
  25. Klijn JG. Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med. Oncol. Tumor Pharmacother. 1984;1:123–128
  26. Celio L, Martinetti A, Ferrari L, et al.  Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor (a comparative endocrine study). Anticancer Res. 1999;19:2261–2268
  27. Garcia-Giralt E, Beuzeboc P, Dieras V, et al.  Phase II trial of decapeptyl (D-TRP-6), a potent lutenizing hormone-releasing hormone analogue in untreated advanced breast cancer. Am. J. Clin. Oncol. 1996;19:455–458
  28. Neskovic-Konstantinovic ZB, Vuletic LB, Nikolic-Stanojevic LI, et al.  Therapeutic and endocrine effects of Decapeptyl, synthetic LH-RH agonistic analogue in premenopausal women with metastatic breast cancer. A pilot phase II study. Oncology. 1994;51:95–101
  29. Robertson JF, Nicholson RI, Walker KJ, Blamey RW. Zoladex in advanced breast cancer. Horm. Res. 1989;32(Suppl 1):206–208
  30. Boccardo F, Rubagotti A, Perrotta A, et al.  Ovarian ablation versus goserelin with or without tamoxifen in pre-/perimenopausal patients with advanced breast cancer (results of a multicentric Italian study). Ann. Oncol. 1994;5:337–342
  31. Jonat W, Kaufmann M, Blamey RW, et al.  A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur. J. Cancer. 1995;31A:137–142
  32. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer (a meta-analysis of four randomized trials). J. Clin. Oncol. 2001;19:343–353
  33. Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 1999;56:25–34
  34. Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer. 1990;62:679–683
  35. Cheung KL, Forward D, Jackson L, Robertson JF. The combined use of goserelin and anastrozole as second-line endocrine therapy in premenopausal women with advanced breast cancer—a study of its clinical and endocrine effects. Eur. J. Cancer. 2001;37(Suppl. 5):8; [abstr O-22]
  36. Early Breast Cancer Trialists’ Collaborative Group . Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189–1196
  37. Kaufmann M. Zoladex™ (goserelin) vs. CMF as adjuvant therapy in pre/perimenopausal node-positive early breast cancer. Preliminary efficacy results from the ZEBRA study. Breast. 2001;10(Suppl. 1):S30; [abstr P53]
  38. Wallwiener D, Possinger K, Bondar G, et al.  Leuprorelin acetate vs. CMF in the adjuvant treatment of premenopausal women with ER/PR-positive, node-positive breast cancer: interim results of the TABLE study. Proc ASCO. 2001;20:34a; [abstr 132]
  39. Jakesz R, Hausmaninger H, Samonigg H, et al. on behalf of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and-negative patients with hormone-responsive breast cancer. Breast 2001, 10(Suppl. 1), S10 [abstr S26].
  40. Boccardo F, Rubagotti A, Amoroso D, et al.  Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients (results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial). J. Clin. Oncol. 2000;18:2718–2727
  41. Roche HH, Kerbrat P, Bonneterre J, et al.  Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (Pts) with positive hormone-receptor (HR+) and 1–3 node-positive (N+) tumor (results of the FASG 06 Trial). Proc ASCO. 2000;19:72a; [abstr 279]
  42. Boccardo F, Rubagotti A, Amoroso M, et al.  CMF vs tamoxifen (TAM) plus ovarian suppression (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients (Pts). Breast. 2001;10(Suppl. 1):S32; [abstr P62]
  43. Baum M, Houghton J, Odling-Smee W, et al. on behalf of the ZIPP Group. Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 2001, 10(Suppl. 1), S32-S33 [abstr P64].
  44. Baum M, Houghton J, Sawyer W, et al.  Management of premenopausal women with early breast cancer. Is there a role for goserelin?. Proc. ASCO. 2001;20:27a; [abstr 103]
  45. Davidson N, O'Neill A, Vukov CK, et al.  Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer (an Eastern Cooperative Oncology Group Phase III intergroup trial (E5188, INT-0101)). Breast. 1999;8:232–233 [abstr 069]
  46. Castiglione-Gertsch M, Gelber RD, O'Neill A, Coates AS, Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. Eur. J. Cancer. 2000;36:549–550
  47. Castiglione-Gertsch M, O'Neill A, Gelber RD, et al.  Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? (first results of the IBCSG trial VIII). Proc ASCO. 2002;21:38a; [abstr 149]
  48. De Matteis A, Montedoro D, Nuzzo F, et al.  Hormonotherapy with goserelin depot after adjuvant chemotherapy in premenopausal women with early breast cancer (Is there any benefit?). Ann. Oncol. 1998;9(Suppl. 4):11; [abstr 52]
  49. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 1996;14:1718–1729
  50. Jakesz R, Hausmaninger H, Samonigg H, et al.  Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proceedings of ASCO. 1999;18:67a; [abstr 250]
  51. Pagani O, O'Neill A, Castiglione M, et al.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement (results of the International Breast Cancer Study Group (IBCSG) Trial VI). Eur. J. Cancer. 1998;34:632–640
  52. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhoea induced by adjuvant chemotherapy in early breast cancer patients (prognostic role and clinical implications). Breast Cancer Res. Treat. 1997;43:183–190
  53. Blamey RW. The design and clinical use of the NottinghamPrognostic Index in breast cancer. Breast. 1996;22:574–577

PII: S0959-8049(02)00810-9

doi: 10.1016/S0959-8049(02)00810-9

European Journal of Cancer
Volume 39, Issue 7 , Pages 861-869 , May 2003

Article Tools

* Image Usage & Resolution